Link to Jukka Westermarck’s Research Profile

Selected Publications

Momeny M, Tienhaara M, Sharma M, Chakroborty D, Varjus R, Takala I, Merisaari J, Padzik A, Vogt A, Paatero I, Elenius K, Laajala TD, Kurppa KJ, Westermarck J. DUSP6 inhibition overcomes Neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer. EMBO Molecular Medicine 16: 1603-1629, 2024

Denisova OV, Merisaari J, Huhtaniemi R, Qiao X, Yetukuri L, Jumppanen M, Kaur A, Pääkkonen M, von Schantz-Fant C, Ohlmeyer M, Wennerberg K, Kauko O, Koch R, Aittokallio T, Taipale M, Westermarck J. PP2A-based triple-strike therapy overcomes mitochondrial apoptosis resistance in brain cancer cells. Molecular Oncology 17(9): 1803-1820, 2023

Cazzoli R, Romeo F, Pallavicini I, Peri S, Romanenghi M, Pérez-Valencia JA, Hagag E, Ferrucci F, Elgendy M, Vittorio O, Pece S, Foiani M, Westermarck J, Minucci S. Endogenous PP2A inhibitor CIP2A degradation by chaperone-mediated autophagy contributes to the antitumor effect of mitochondrial complex I inhibition. Cell Reports 42(6): 112616, 2023

Aakula A, Sharma M, Tabaro F, Nätkin R, Kamila J, Honkanen H, Schapira M, Arrowsmith C, Nykter M, Westermarck J. RAS and PP2A activities converge on epigenetic gene regulation. Life Science Alliance, 2023 March1

Pavic K, Gupta N, Domènech Omella J, Derua R, Aakula A, Huhtaniemi R, Määttä JA, Höfflin N, Okkeri J, Wang Z, Kauko O, Varjus R, Honkanen H, Abankwa D, Köhn M, Hytönen VP, Xu W, Nilsson J, Page R, Janssens V, Leitner A, and Westermarck J. Structural mechanism for inhibition of PP2A-B56a and oncogenicity by CIP2A. Nature Communications, 2023 Feb 28.

Laine A, Nagelli SG, Farrington C, Butt U, Cvrljevic AN, Vainonen JP, Feringa FM, Grönroos TJ, Gautam P, Khan S, Sihto H, Qiao X, Pavic K, Connolly DC, Kronqvist P,  Elo LL, Maurer J, Wennerberg K, Medema RH, Joensuu H, Peuhu E, de Visser K, Narla G, Westermarck J. CIP2A interacts with TopBP1 and drives basal-like breast cancer tumorigenesis. Cancer Res. 2021 Jun 18

Vervoort SJ, Welsh SA, Devlin JR, Barbieri E, Knight DA, Offley S, Bjelosevic S, Costacurta M, Todorovski I, Kearney CJ, Sandow JJ, Fan Z, Blyth B, McLeod V, Vissers JHA, Pavic K, Martin BP, Gregory G, Demosthenous E, Zethoven M. Kong IY, Hawkins ED, Hogg SJ, Kelly MJ, Newbold A, Simpson KJ, Kauko O, Harvey KF, Ohlmeyer M, Westermarck J, Gray N, Gardini A, Johnstone RW. The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer. Cell. 2021 May 12

Makela E, Pavic K, Varila TM, Salmenniemi U, Loyttyniemi E, Nagelli SG, Ammunet T, Kahari VM, Clark RE, Elo LL, Bachanaboyina VK, Lucas CM, Itala-Remes M, Westermarck J. Discovery of a Novel CIP2A Variant (NOCIVA) with clinical relevance in predicting TKI resistance in myeloid leukemias. Clin Cancer Res. 2021 Mar 5.

Kauko O, Imanishi SY, Kulesskiy E, Yetukuri L, Laajala TD, Sharma M, Pavic K, Aakula A, Rupp C, Jumppanen M, Haapaniemi P, Ruan L, Yadav B, Suni V, Varila T, Corthals GL, Reimand J, Wennerberg K, Aittokallio T, Westermarck J. Phosphoproteome and drug response effects mediated by the three Protein Phosphatase 2A inhibitor proteins CIP2A, SET and PME-1. J Biol Chem. 2020 Feb 18.

Qiao X, Liu Y, Llamazares Prada M, Mohan AK, Gupta A, Jaiswal A, Sharma M, Merisaari J, Haikala HM, Talvinen K, Yetukuri L, Pylvänäinen JW, Klefström J, Kronqvist P, Meinander A, Aittokallio T, Hietakangas V, Eilers M, Westermarck J. UBR5 is co-amplified with MYC in breast tumors and encodes an ubiquitin ligase that limits MYC-dependent apoptosis. Cancer Res. 2020 Feb 6.

Kerosuo L, Neppala P, Hsin J, Mohlin S, Vieceli FM, Török Z, Laine A, Westermarck J and Bronner ME,  Enhanced expression of MycN/CIP2A drives neural crest toward a neural stem cell-like fate: Implications for priming of neuroblastoma. Proc Natl Acad Sci U S A. 2018 Jul 18

Kauko O, O’Connor KM, Kulesskiy E, Sangodkar J, Aakula A, Izadmehr S, Yetukuri L, Yadav B, Padzik A, Laajala TD, Haapaniemi P, Momeny M, Varila T, Ohlmeyer M, Aittokallio T, Wennerberg K, Narla G, and Westermarck J; PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. Sci Transl Med. 2018 Jul 18;10(450)

Shentu YP, Huo Y, Feng XL, Gilbert J, Zhang Q, Liuyang ZY, Wang XL, Wang G, Zhou H, Wang XC, Wang JZ, Lu YM, Westermarck J, Man HY, Liu R. CIP2A Causes Tau/APP Phosphorylation, Synaptopathy, and Memory Deficits in Alzheimer’s Disease. Cell Rep. 2018 Jul 17;24(3):713-723

Wang J, Okkeri J, Pavic K, Wang Z, Kauko O, Halonen T, Sarek G, Ojala PM, Rao Z, Xu W, Westermarck J; Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56. EMBO Rep. 2017 Mar.18(3:437-450

Laine A, Sihto H, Come C, Rosenfeldt MT, Zwolinska A, Niemelä M, Khanna A, Chan EK, Kähäri VM, Kellokumpu-Lehtinen PL, Sansom OJ, Evan GI, Junttila MR, Ryan KM, Marine JC, Joensuu H, Westermarck J. Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. Cancer Discov. 2013 Jan 10;3(2):182-97

Junttila, MR, Puustinen P, Niemelä M, Ahola R, Arnold H, Böttzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, Lu SL, Li S, Chan EKL, Wang X-J, Grenman R, Kast J, Kallunki T, Sears R, Kähäri V-M, Westermarck J; CIP2A Inhibits PP2A in Human Malignancies. Cell 130 51–62, 2007.

Reviews

Nagelli S, Westermarck J. CIP2A coordinates phosphosignaling, mitosis, and the DNA damage response. Trends Cancer.2024 Jan;10(1):52-64.

Vainonen J, Momeny M, Westermarck J. Druggable cancer phosphatases. Sci Transl Med. 2021 Apr 7.

Kurppa, KJ, & Westermarck, J. Good Guy in Bad Company: How STRNs Convert PP2A into an Oncoprotein. Cancer cell, 38(1), 20–22

Westermarck J, Neel BG. Piecing Together a Broken Tumor Suppressor Phosphatase for Cancer Therapy. Cell. 2020 Apr 30;181(3):514-7.

Kauko, O and Westermarck J. Non-genomic mechanisms of Protein Phosphatase 2A (PP2A) regulation in cancer. Int J Biochem Cell Biol. 2018 Mar;96:157-164

Kaur A and Westermarck J. Regulation of protein phosphatase 2A (PP2A) tumor suppressor function by PME-1. Biochemical Society Transactions 44(6): 1683-1693, 2016.